0001213900-23-088775 | 10-Q | XBRL Viewer

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

The stock option activity for the period ended September 30, 2023 is as follows:

	Number of Options		Weighted- Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in Years)
Outstanding as of December 31, 2022		50,098	$	75.20		7.09
Granted		13,550	$	20.04		10.00
Outstanding as of September 30, 2023		63,648	$	63.46		6.98
Exercisable at September 30, 2023		33,578	$	78.79		5.37

Schedule of Restricted Stock Unit Activity

The restricted stock unit activity for the period ended September 30, 2023 is as follows:

	Number of Shares		Weighted- Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in Years)
Outstanding as of December 31, 2022		-	$	-		-
Granted		13,825	$	25.60		10.00
Outstanding of September 30, 2023		13,825	$	25.60		9.42
Exercisable at September 30, 2023		-	$	-		-

Related Party Transactions

9 Months Ended

Sep. 30, 2023

Related Party Transactions

Note 6 – Related Party Transactions

At September 30, 2023 and December 31, 2022, the Company had the following outstanding payables to its shareholders for past services, which are included within the Company’s accounts payable above:

	September 30,		December 31,
	2023		2022
Genomic Diagnostic Technologies	$	-	$	925
St. Laurent Institute		-		232,418
St. Laurent Realty, Inc.		7,558		7,558
	$	7,558	$	240,901

The above entities are affiliated with (1) William C. St. Laurent, a former member of the Company’s board of directors, (2) relatives of Mr. St. Laurent or (3) entities controlled by the St. Laurent family. St. Laurent Realty, Inc. and Genomic Diagnostic Technologies assisted the Company by previously providing corporate accounting support; St. Laurent Institute, a non-for-profit company, provided bioinformatics specialist support for certain sequencing services.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Notes Payable (Details) - USD ($)	3 Months Ended		9 Months Ended
Notes Payable (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 29, 2020
Notes Payable (Details) [Line Items]
Non-convertible promissory notes					$ 1,375,000
Due date			Oct. 01, 2021
Interest expense		$ 17,188
Maximum [Member]
Notes Payable (Details) [Line Items]
Promissory note rate	10.00%		10.00%
Minimum [Member]
Notes Payable (Details) [Line Items]
Promissory note rate	5.00%		5.00%
Promissory Notes [Member]
Notes Payable (Details) [Line Items]
Interest expense	$ 17,188		$ 51,181	$ 73,560

Stock-based Compensation

9 Months Ended

Sep. 30, 2023

Stock-based Compensation [Abstract]

Stock-based Compensation

Note 5 – Stock-based Compensation

The Company’s 2014 Equity Incentive Plan (the “2014 Plan”) permits the grant of options and restricted stock units for its common stock and shares of common stock to its employees, board members and consultants for up to 87,500 shares.

As of September 30, 2023, there were 10,027 shares available for future issuance under the 2014 Plan. Generally, option awards are granted with an exercise price equal to the fair value of the Company’s stock at the date of grant and vest over a period of three to four years. No option may have a term in excess of ten years from the option grant date. Certain option and share awards provide for accelerated vesting if there is a change in control (as defined by the 2014 Plan). The weighted average grant date fair value of options granted in the nine-month period ended September 30, 2023 was $11.60 per share.

The stock option activity for the period ended September 30, 2023 is as follows:

	Number of Options		Weighted- Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in Years)
Outstanding as of December 31, 2022		50,098	$	75.20		7.09
Granted		13,550	$	20.04		10.00
Outstanding as of September 30, 2023		63,648	$	63.46		6.98
Exercisable at September 30, 2023		33,578	$	78.79		5.37

The restricted stock unit activity for the period ended September 30, 2023 is as follows:

	Number of Shares		Weighted- Average Exercise Price per Share		Weighted Average Remaining Contractual Term (in Years)
Outstanding as of December 31, 2022		-	$	-		-
Granted		13,825	$	25.60		10.00
Outstanding of September 30, 2023		13,825	$	25.60		9.42
Exercisable at September 30, 2023		-	$	-		-

During the three-month periods ended September 30, 2023 and 2022, the Company recorded $106,183 and $66,996, respectively, of stock-based compensation associated with stock options and restricted stock units, of which $54,167 and $46,394 were included in general and administrative expenses for the three-month periods ended September 30, 2023 and 2022, respectively, and $52,016 and $20,602 were included in research and development expenses for the three-month periods ended September 30, 2023 and 2022, respectively.

During the nine-month periods ended September 30, 2023 and 2022, the Company recorded $295,210 and $189,905, respectively, of stock-based compensation associated with stock options and restricted stock units, of which $160,106 and $131,533 were included in general and administrative expenses for the nine-month periods ended September 30, 2023 and 2022, respectively, and $135,104 and $58,372 were included in research and development expenses for the nine-month periods ended September 30, 2023 and 2022, respectively.

As of September 30, 2023, there was approximately $639,812 and $285,102 of unrecognized compensation expense related to unvested stock options and restricted stock units, respectively, which will be recognized over a weighted average period of approximately 1.31 years. The recognition of the unrecognized compensation expense related to unvested stock options and restricted stock units is 1.27 years and 1.34 years, respectively.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 300,750

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 9 – Commitments and Contingencies

Operating Leases

The Company’s office space lease in Woburn, Massachusetts (the “Woburn Lease”) for the Company’s corporate headquarters was on a month-to-month basis since November 2020 and was terminated in February 2022. The rent expense for this lease was $0 for the three months ended September 30, 2023 and 2022, and $0 and $14,239 for the nine months ended September 30, 2023 and 2022, respectively.

On February 2, 2022, the Company entered into a lease agreement for approximately 15,638 square feet of its new corporate office space in Billerica, Massachusetts (the “Billerica Lease”). The Billerica Lease has a term of 92 months from its effective date and included access to certain additional office space until August 1, 2022. In addition, the Company is required to share in certain taxes and operating expenses of the Billerica Lease.

The Billerica Lease is classified as an operating lease. At the inception date of the Billerica Lease, the Company recorded a right-of-use asset of $1,481,646 in operating lease right-of-use asset, as well as a lease liability of $12,222 in current liabilities and $1,547,614 in long-term liabilities. The operating lease right-of use asset is less than that of the Company’s lease liabilities as of the lease inception date. This is due to the fact that the Company as part of the Billerica Lease was allowed certain tenant improvement allowances, which amounted to $78,190 at lease inception. This lease liability represented the net present value of future lease payments for the lease utilizing a discount rate of 5.98%, which corresponded to the Company’s incremental borrowing rate.

In August 2022, the Company received the tenant improvement allowance from the landlord, which totaled approximately $312,760. This allowance covered the leasehold improvements to the Billerica space and was accounted for as a reduction to the right-of-use asset.

As of September 30, 2023, the remaining lease term was 6 years.

The Company recorded expense related to the Billerica Lease in the amount of $54,641 and $163,921 for the three-and nine-month periods ended September 30, 2023, respectively, and $41,893 and $145,709 for the three-and nine-month periods ended September 30, 2022, respectively.

The Company made cash payments of $42,950 and $128,851 during the three- and nine-month periods ended September 30, 2023, respectively, and cash payments of $7,850 and $45,418 during the three- and nine-month periods ended September 30, 2022, respectively, for amounts included in the measurement of lease liabilities.

As of September 30, 2023, the Company has presented $193,412 in current portion of operating lease liability and $1,298,237 in operating lease liability, less current portion.

Finance Lease

On May 1, 2023, the Company entered into a lease agreement for laboratory equipment (the “Equipment Lease”). The Equipment Lease has a term of 36 months from its effective date, and an end of lease purchase option of $1. The Equipment Lease was classified as a finance lease. At the inception date of the Equipment Lease, the Company recorded a right-of-use asset of $187,497 in property and equipment, net, as well as a lease liability of $52,881 in current liabilities and $97,110 in long-term liabilities. The finance lease right of use asset is more than that of the Company’s lease liabilities at the inception of the lease due to a prepayment on the lease made by the Company of $37,506. The lease liability represented the net present value of future lease payments over the lease term utilizing a discount rate of 17.44%, which corresponded to the rate implicit to the lease.

As of September 30, 2023, the remaining lease term was 2.50 years.

The Company recorded expense related to the Equipment Lease in the amount of $14,524 and $29,559 for the three-and nine-month periods ended September 30, 2023, respectively.

The Company made cash payments of $18,094 and $36,188 during the three- and nine-month periods ended September 30, 2023, respectively.

Interest expense related to the Equipment Lease totaled $5,149 and $10,809 for the three- and nine-month periods ended September 30, 2023. The equipment is included in Property and equipment, net and is depreciated on a straight-line basis over a five-year period. The Company amortizes the equipment over its useful life as the Company is reasonably certain to exercise the $1 purchase option for the equipment at the end of the lease term.

Depreciation expense related to finance lease assets totaled $9,375 and $18,750 for the three- and nine-month periods ended September 30, 2023, and $0 for the three-and nine-month periods ended September 30, 2022.

As of September 30, 2023, the Company has presented $57,309 in current portion of finance lease liability and $67,305 in finance lease liability, less current portion.

The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2023:

	Operating Lease		Finance Lease
2023 (remaining)	$	68,455	$	18,094
2024		275,875		72,375
2025		284,151		54,281
2026		292,676		-
2027		301,456		-
Thereafter		548,577		-
Total undiscounted lease liabilities	$	1,771,190	$	144,750
Less effects of discounting		279,541		20,136
Total lease liabilities	$	1,491,649	$	124,614

Fair Value Measurements (Details) - Schedule of Assets Measured at Fair Value - U.S. government and agency obligations [Member]	Dec. 31, 2022 USD ($)
Fair Value Measurements [Line Items]
Assets, Fair Value	$ 4,036,014
Level 1 [Member]
Fair Value Measurements [Line Items]
Assets, Fair Value	4,036,014
Level 2 [Member]
Fair Value Measurements [Line Items]
Assets, Fair Value
Level 3 [Member]
Fair Value Measurements [Line Items]
Assets, Fair Value

Accrued Expenses

9 Months Ended

Sep. 30, 2023

Accrued Expenses [Abstract]

Accrued Expenses

Note 3 – Accrued Expenses

Accrued expenses consisted of the following:

	September 30,		December 31,
	2023		2022
Accrued interest	$	358,003	$	306,821
Accrued bonuses		-		135,000
Other		-		53,641
	$	358,003	$	495,462

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 3	$ 22,596,216		$ (14,413,851)	$ 8,182,368
Balance (in Shares) at Dec. 31, 2021	330,648
Stock-based compensation expense		55,914			55,914
Net loss				(937,954)	(937,954)
Balance at Mar. 31, 2022	$ 3	22,652,130		(15,351,805)	7,300,328
Balance (in Shares) at Mar. 31, 2022	330,648
Balance at Dec. 31, 2021	$ 3	22,596,216		(14,413,851)	8,182,368
Balance (in Shares) at Dec. 31, 2021	330,648
Other comprehensive income
Net loss					(2,858,818)
Balance at Sep. 30, 2022	$ 3	22,786,121		(17,272,669)	5,513,455
Balance (in Shares) at Sep. 30, 2022	330,648
Balance at Mar. 31, 2022	$ 3	22,652,130		(15,351,805)	7,300,328
Balance (in Shares) at Mar. 31, 2022	330,648
Stock-based compensation expense		66,995			66,995
Net loss				(994,915)	(994,915)
Balance at Jun. 30, 2022	$ 3	22,719,125		(16,346,720)	6,372,408
Balance (in Shares) at Jun. 30, 2022	330,648
Stock-based compensation expense		66,996			66,996
Other comprehensive income
Net loss				(925,949)	(925,949)
Balance at Sep. 30, 2022	$ 3	22,786,121		(17,272,669)	5,513,455
Balance (in Shares) at Sep. 30, 2022	330,648
Balance at Dec. 31, 2022	$ 3	22,853,116	22,451	(18,508,684)	4,366,886
Balance (in Shares) at Dec. 31, 2022	330,648
Stock-based compensation expense		82,594			82,594
Issuance of common stock, net of issuance costs of $300,750	$ 1	1,499,249			1,499,250
Issuance of common stock, net of issuance costs of $300,750 (in Shares)	50,000
Other comprehensive income			(4,512)		(4,512)
Net loss				(1,718,366)	(1,718,366)
Balance at Mar. 31, 2023	$ 4	24,434,959	17,939	(20,227,050)	4,225,852
Balance (in Shares) at Mar. 31, 2023	380,648
Balance at Dec. 31, 2022	$ 3	22,853,116	22,451	(18,508,684)	4,366,886
Balance (in Shares) at Dec. 31, 2022	330,648
Other comprehensive income					22,451
Net loss					(4,386,148)
Balance at Sep. 30, 2023	$ 4	24,647,575		(22,894,832)	1,752,747
Balance (in Shares) at Sep. 30, 2023	380,648
Balance at Mar. 31, 2023	$ 4	24,434,959	17,939	(20,227,050)	4,225,852
Balance (in Shares) at Mar. 31, 2023	380,648
Stock-based compensation expense		106,433			106,433
Other comprehensive income			(17,939)		(17,939)
Net loss				(1,400,114)	(1,400,114)
Balance at Jun. 30, 2023	$ 4	24,541,392		(21,627,164)	2,914,232
Balance (in Shares) at Jun. 30, 2023	380,648
Stock-based compensation expense		106,183			106,183
Other comprehensive income
Net loss				(1,267,668)	(1,267,668)
Balance at Sep. 30, 2023	$ 4	$ 24,647,575		$ (22,894,832)	$ 1,752,747
Balance (in Shares) at Sep. 30, 2023	380,648

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482659/740-20-45-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482659/740-20-45-2

+ Details

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

Common Stock Warrants (Tables)

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Schedule of Outstanding Warrants to Purchase Common Stock

The following table summarizes information with regard to outstanding warrants to purchase the Company’s common stock as of September 30, 2023. All warrants are accounted for as equity based on the U.S. GAAP guidance applicable to the instruments indexed to an entity’s own stock.

	Number of
	Shares
	Issuable
	Upon
	Exercise of
	Outstanding		Exercise
Issuance Date	Warrants		Price		Expiration Date
10/17/2018		29	$	124.00	10/16/2023
11/2/2018		24	$	124.00	11/1/2023
11/9/2018		24	$	124.00	11/8/2023
11/16/2018		24	$	124.00	11/15/2023
11/29/2018		24	$	124.00	11/28/2023
12/21/2018		24	$	124.00	12/20/2023
12/27/2018		24	$	124.00	12/26/2023
1/31/2019		48	$	124.00	1/30/2024
2/7/2019		41	$	124.00	2/6/2024
2/21/2019		41	$	124.00	2/20/2024
3/20/2019		84	$	124.00	3/18/2024
4/8/2019		48	$	124.00	4/6/2024
11/19/2020		1,333	$	164.00	6/30/2024
11/19/2020		213	$	164.00	6/30/2024
1/8/2021		333	$	164.00	6/30/2024
1/11/2021		667	$	164.00	6/30/2024
2/13/2021		333	$	164.00	6/30/2024
3/16/2021		267	$	164.00	6/30/2024
3/16/2021		333	$	164.00	6/30/2024
8/31/2021		87,975	$	170.00	8/31/2026
8/31/2021		3,825	$	187.00	8/26/2026
9/29/2021		236	$	187.00	8/26/2026
		95,950

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows from Operating Activities
Net loss	$ (4,386,148)	$ (2,858,818)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation	112,905	58,718
Write-off of obsolete inventory	165,852
Unrealized gain on marketable equity securities		(54,266)
Realized (gain)/loss on marketable debt and equity securities	(106,051)	106,324
Provision for bad debts	78,491
Stock-based compensation	295,210	189,905
Non-cash lease expense	35,071	100,291
Changes in operating assets and liabilities
Accounts receivable, net		1,200
Other receivables		(25,035)
Prepaid expenses	134,353	(36,775)
Inventory		(22,749)
Other assets	39,623	(77,271)
Accounts payable	(216,716)	(287,791)
Accrued expenses	(137,459)	(7,304)
Net cash used in operating activities	(3,984,869)	(2,913,571)
Cash Flows from Investing Activities
Purchases of lab equipment	(61,989)	(29,657)
Purchases of marketable debt securities	(2,800,386)	(2,500,517)
Proceeds from sales of marketable equity securities		5,882,138
Maturity of marketable debt securities	6,920,000
Net cash provided by investing activities	4,057,625	3,351,964
Cash Flows from Financing Activities
Proceeds from issuance of common stock, gross	1,800,000
Payment for issuance costs of common stock	(300,750)
Repayments of finance lease liability	(25,377)
Net cash provided by financing activities	1,473,873
Net increase in cash and cash equivalents	1,546,629	438,393
Cash and cash equivalents, beginning of period	2,180,525	4,015,128
Cash and cash equivalents, end of period	3,727,154	4,453,521
Supplemental disclosure of cash flow information and non-cash financing transactions
Right-of-use asset acquired through operating lease		1,257,495
Fixed assets acquired through finance lease	$ 187,497
Leasehold improvements financed through tenant improvement allowance		$ 312,760

Related Party Transactions (Details) - Schedule of Outstanding Payables - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Total related party payables	$ 7,558	$ 240,901
Genomic Diagnostic Technologies [Member]
Related Party Transaction [Line Items]
Total related party payables		925
St. Laurent Institute [Member]
Related Party Transaction [Line Items]
Total related party payables		232,418
St. Laurent Realty, Inc. [Member]
Related Party Transaction [Line Items]
Total related party payables	$ 7,558	$ 7,558

Commitments and Contingencies (Details)			3 Months Ended		9 Months Ended
Commitments and Contingencies (Details)	May 01, 2023 USD ($)	Feb. 02, 2022 m²	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Aug. 31, 2022 USD ($)
Commitments and Contingencies (Details) [Line Items]
Rent expense for lease			$ 0	$ 0	$ 0	$ 14,239
Office space (in Square Meters) \| m²		15,638
Lease term		92 months
Operating lease right-of-use asset					1,481,646
Lease liabilities					12,222
Long-term liabilities			1,547,614		1,547,614
Lease inception			$ 78,190		$ 78,190
Lease utilizing a discount rate					5.98%
Land improvement							$ 312,760
Remaining lease term			6 years		6 years
Lease expense			$ 54,641	41,893	$ 163,921	145,709
Cash payments			42,950	7,850	128,851	45,418
Operating lease liability					193,412
Equipment lease term	36 months
Purchase option of lease term	$ 1				1
Right of use asset	187,497
Lease liability	52,881
Long-term liabilities	97,110
Lease due to prepayment	$ 37,506
Percentage of lease term	17.44%
Equipment Lease amount			14,524		29,559
Cash payments			18,094		36,188
Depreciation expense			9,375	$ 0	18,750	$ 0
Finance lease liability					67,305
Operating Lease [Member]
Commitments and Contingencies (Details) [Line Items]
Operating lease liability					1,298,237
Finance Lease [Member]
Commitments and Contingencies (Details) [Line Items]
Lease inception			$ 144,750		$ 144,750
Remaining lease term			2 years 6 months		2 years 6 months
Interest expense			$ 5,149		$ 10,809
Finance lease liability					$ 57,309

Common Stock Warrants

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Common Stock Warrants

Note 8 – Common Stock Warrants

	Number of
	Shares
	Issuable
	Upon
	Exercise of
	Outstanding		Exercise
Issuance Date	Warrants		Price		Expiration Date
10/17/2018		29	$	124.00	10/16/2023
11/2/2018		24	$	124.00	11/1/2023
11/9/2018		24	$	124.00	11/8/2023
11/16/2018		24	$	124.00	11/15/2023
11/29/2018		24	$	124.00	11/28/2023
12/21/2018		24	$	124.00	12/20/2023
12/27/2018		24	$	124.00	12/26/2023
1/31/2019		48	$	124.00	1/30/2024
2/7/2019		41	$	124.00	2/6/2024
2/21/2019		41	$	124.00	2/20/2024
3/20/2019		84	$	124.00	3/18/2024
4/8/2019		48	$	124.00	4/6/2024
11/19/2020		1,333	$	164.00	6/30/2024
11/19/2020		213	$	164.00	6/30/2024
1/8/2021		333	$	164.00	6/30/2024
1/11/2021		667	$	164.00	6/30/2024
2/13/2021		333	$	164.00	6/30/2024
3/16/2021		267	$	164.00	6/30/2024
3/16/2021		333	$	164.00	6/30/2024
8/31/2021		87,975	$	170.00	8/31/2026
8/31/2021		3,825	$	187.00	8/26/2026
9/29/2021		236	$	187.00	8/26/2026
		95,950

During the nine-month period September 30, 2023, warrants to purchase 12,162 and 1,590 of common stock with exercise prices of $86.40 and $124.00, respectively, expired.

During the nine-month period September 30, 2022, warrants to purchase 130 shares of common stock with an exercise price of $124.00 expired.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Significant Accounting Policies (Details) - Schedule of Inventory - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Schedule of Inventory [Abstract]
Raw materials		$ 114,175
Work in process		51,677
Total inventory		$ 165,852

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net loss per share - diluted	$ (3.33)	$ (2.80)	$ (11.78)	$ (8.65)
Weighted average common shares - diluted	380,648	330,648	372,406	330,648

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 3,727,154	$ 2,180,525
Marketable securities		4,036,014
Accounts receivable, net of allowance for doubtful accounts of $24,507 and $6,016 as of September 30, 2023 and December 31, 2022, respectively	2,723	21,214
Other receivables		60,000
Inventory		165,852
Prepaid expenses		171,859
Total current assets	3,729,877	6,635,464
Other assets
Property and equipment, net	666,689	530,108
Operating lease right-of-use asset	1,031,836	1,129,715
Other assets	79,331	118,954
Total assets	5,507,733	8,414,241
Current liabilities
Accounts payable	405,720	622,436
Accrued expenses	358,003	495,462
Current portion of finance lease liability	57,309
Current portion of operating lease liability	193,412	110,114
Total current liabilities	1,014,444	1,228,012
Non-current liabilities
Finance lease liability, less current portion	67,305
Operating lease liability, less current portion	1,298,237	1,444,343
Non-convertible promissory notes - long-term	1,375,000	1,375,000
Total non-current liabilities	2,740,542	2,819,343
Total liabilities	3,754,986	4,047,355
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.00001 par value; 300,000,000 shares authorized; 380,648 and 330,648 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	4	3
Additional paid-in capital	24,647,575	22,853,116
Accumulated deficit	(22,894,832)	(18,508,684)
Accumulated other comprehensive income		22,451
Total stockholders’ equity	1,752,747	4,366,886
Total liabilities and stockholders’ equity	$ 5,507,733	$ 8,414,241

Stock-based Compensation (Details) - Schedule of Stock Option Activity	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Schedule Of Stock Option Activity Abstract
Number of Options, Outstanding Beginning \| shares	50,098
Weighted- Average Exercise Price per Share, Outstanding Beginning \| $ / shares	$ 75.2
Weighted Average Remaining Contractual Term (in Years), Outstanding Beginning	7 years 1 month 2 days
Number of Options, Granted \| shares	13,550
Weighted- Average Exercise Price per Share, Granted \| $ / shares	$ 20.04
Weighted Average Remaining Contractual Term (in Years), Granted	10 years
Number of Options, Outstanding Ending \| shares	63,648
Weighted- Average Exercise Price per Share, Outstanding Ending \| $ / shares	$ 63.46
Weighted Average Remaining Contractual Term (in Years), Outstanding Ending	6 years 11 months 23 days
Number of Options, Exercisable \| shares	33,578
Weighted- Average Exercise Price per Share, Exercisable \| $ / shares	$ 78.79
Weighted Average Remaining Contractual Term (in Years), Exercisable	5 years 4 months 13 days

Nature of Operations and Basis of Presentation

9 Months Ended

Sep. 30, 2023

Nature of Operations and Basis of Presentation [Abstract]

Nature of Operations and Basis of Presentation

Note 1 – Nature of Operations and Basis of Presentation

SeqLL Inc. was incorporated as a Delaware corporation on April 3, 2014. On April 8, 2014, SeqLL Inc. acquired a 100% ownership interest in SeqLL, LLC (“Subsidiary”), a domestic limited liability company formed on March 11, 2013 in the State of Massachusetts. SeqLL Inc. is a holding company of the Subsidiary (together the “Company”, SeqLL”, “we”, “us” or “our”) and is a life sciences company focused on the development and application of innovative genetic analysis technologies and the monetization of that technology and related intellectual property. The Subsidiary owns technology to enable the analysis of large volumes of genetic material by directly sequencing single molecules of DNA or RNA. The Subsidiary’s principal office is located in Billerica, Massachusetts.

On April 26, 2023, SeqLL Merger LLC (“SeqLL Merger Sub”) was formed in the State of Delaware as a wholly-owned subsidiary of the Company. SeqLL Merger Sub was formed solely for the purpose of completing the Merger (defined below). SeqLL Merger Sub has not carried on any activities as of September 30, 2023, except for activities incidental to its formation and activities undertaken in connection with the Merger Agreement (defined below) and the Merger.

On August 30, 2023, the Company executed one-for-40 reverse stock split. Please refer to the below for further detail.

Proposed Merger

On May 29, 2023, the Company, SeqLL Merger LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (“Purchaser Sub”), Atlantic Acquisition Corp, a Delaware corporation (“Atlantic”), Atlantic Merger LLC, a Delaware limited liability company and a majority-owned subsidiary of Atlantic (“Atlantic Merger Sub”), Lyneer Investments, LLC, a Delaware limited liability company (“Lyneer”), IDC Technologies, Inc., a California corporation (“IDC”), and Lyneer Management Holdings LLC, a Delaware limited liability company (“Lyneer Management”), entered into an Agreement and Plan of Reorganization (as amended, the “Merger Agreement”), pursuant to which (i) Atlantic Merger Sub will be merged with and into Lyneer, with Lyneer continuing as the surviving entity (the “Lyneer Merger”), and (ii) Purchaser Sub will subsequently be merged with and into Lyneer, with Lyneer continuing as the surviving entity and as a wholly-owned subsidiary of the Company (the “SeqLL Merger” and, together with the Lyneer Merger, the “Mergers”).

The Merger Agreement contains customary representations and warranties from the parties, and each party has agreed to customary covenants applicable to such party, including, among others, covenants relating to (i) the conduct of their respective businesses in the ordinary course prior to the effective time of the Mergers and (ii) the requirement of each party to maintain and preserve intact their respective business organizations, assets, properties and material business relations.

The obligation of each of the Company, Atlantic and Lyneer, and their respective subsidiaries, to complete the Mergers is subject to the fulfillment (or waiver, to the extent permissible under applicable law) of certain customary closing conditions, plus the conditions that (i) the stockholders of the Company shall have approved the issuance of the shares of the Company’s common stock in the Mergers, (ii) the Company completes the Capital Raise to certain amount of gross proceeds as defined in the Merger Agreement, part of which will be used to pay the Cash Consideration, and (iii) the continued listing of the Company’s common stock on the Nasdaq Capital Market following the Mergers.

The Merger Agreement, as amended to the date hereof, contains certain termination rights, including (i) by mutual consent of the Company, Atlantic, IDC and Lyneer Management, (ii) by any of the Company, Atlantic, IDC or Lyneer Management upon a material breach of the representations or of any covenants or agreements of certain other parties, (iii) by any of the Company, Atlantic, IDC or Lyneer Management if the Mergers have not been consummated by November 30, 2023 (the “Termination Date”), (iv) by any of the Company, Atlantic, IDC or Lyneer Management if any governmental authority shall have issued an order or taken any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by the Merger Agreement, (v) by any of the Company, Atlantic, IDC or Lyneer Management if the special meeting of the Company’s stockholders has been held and the approval of the issuance of the common stock of the Company in the Mergers and the change of control of the Company that will be effected as a result of such issuance and certain other proposals contemplated by the related proxy statement was not approved, or (vi) by Atlantic, IDC or Lyneer Management if the Company is in breach of the rules and regulations of the Nasdaq Stock Market LLC (“Nasdaq”) or has received a notice from Nasdaq relating to the delisting or maintenance of listing of the Company’s common stock on Nasdaq and the Company fails to cure and maintain its listing on Nasdaq prior to the closing of the Mergers.

The terms of the Merger Agreement as further disclosed and described in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be accessed by the public over the Internet at the SEC’s website at http:/www.sec.gov or on the Company’s website at www.seqll.com/.

Reverse Stock Split

On August 29, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation to (i) effect a reverse stock split of its issued common stock, par value $0.00001 per share (“Common Stock”), in the ratio of one-for-40 (the “Reverse Stock Split”) to be effective at 11:59 p.m., eastern time, on August 30, 2023, and (ii) to increase the authorized capital stock of the Company to 320,000,000 shares, of which 300,000,000 shares shall be Common Stock, and 20,000,000 shares shall be Preferred Stock (the “Capital Stock Increase”). The Common Stock began trading on a split-adjusted basis at the market open on August 31, 2023.

The Reverse Stock Split and the Capital Stock Increase were approved by the stockholders as part of the Special Meeting. No fractional shares were issued as a result of the Reverse Stock Split. Instead, any fractional shares that would have resulted from the Reverse Stock Split were rounded up to the nearest whole number. The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s outstanding Common Stock, except for adjustments that may have resulted from the treatment of fractional shares.

All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-40 reverse stock split.

Asset Purchase Agreement

In connection with the execution and delivery of the Merger Agreement, the Company entered into an asset purchase agreement (“Asset Purchase Agreement”) with SeqLL Omics, Inc., a Delaware corporation (“SeqLL Omics”) on May 29, 2023. SeqLL Omics was formed by Daniel Jones, the Chairman of the Board and Chief Executive Officer of the Company, and certain other Company employees, for the purpose of carrying on the Company’s pre-Merger business after the Mergers. Subject to the terms and conditions of the Asset Purchase Agreement, SeqLL Omics has agreed to purchase from the Company, and the Company has agreed to sell to SeqLL Omics, for a purchase price of $1,000, all of the Company’s rights, title and interests in the assets and properties of the Company as it exists immediately prior to consummation of the Mergers, excluding cash and cash equivalents, including without limitation:

●

all inventory;

●

all leasehold interests in real estate;

●

all contracts with customers, vendors and suppliers and all technology license agreements;

●

all intellectual property and general intangibles;

●

all equipment and other tangible assets used in, or related to, its business operations; and

●

all accounts receivable.

In addition to keeping its cash and cash equivalents in order to make a cash dividend to the Company’s stockholders, the Company will not sell or transfer, and SeqLL Omics will not acquire, certain contracts unrelated to the Company’s pre-Merger business operations, the Company’s corporate records or its rights under the Merger Agreement.

Pursuant to the Asset Purchase Agreement, SeqLL Omics will assume from the Company all obligations or liabilities of the Company related to its pre-Merger business operations, including those under the contracts and leases that it will purchase, other than the following:

●

obligations to pay any rent pursuant to the Company’s real estate lease prior to the first anniversary of the closing under the Asset Purchase Agreement;

●

all obligations of the Company under the Merger Agreement;

●

obligations of the Company that are not related to the Company’s current business operations and arise following the closing;

●

amounts payable under the promissory note of the Company in the principal amount of $1,375,000 payable to St. Laurent Investments LLC, an entity affiliated with William C. St. Laurent, one of the founders and (directly and through affiliates) a principal stockholder of the Company; and

●

any obligations under the excluded contracts.

The Company will be responsible for the payment of transfer taxes, if any, related to the transfer of the transferred assets.

Common Stock Issuance

On February 15, 2023, the Company issued 50,000 shares of common stock to investors, after the reflection of the Reverse Stock Split, at a price of $36.00 per share. The gross proceeds of the issuance was $1,800,000. The Company incurred offering costs of $300,750.

Delisting from the Nasdaq Stock Market

On September 8, 2023, the Company received a letter from the Staff regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”), which requires the Company to have a minimum of 500,000 publicly held shares, exclusive of shares held by officers, directors and 10% stockholders. The letter from Nasdaq indicated that according to its calculations, as of September 7, 2023, the Company no longer met the requirements of the Rule. On September 18, 2023, the Company received a letter from the Listing Qualifications Staff of Nasdaq that supplemented the letter of September 8, 2023 and requested that the Company submit a letter to Nasdaq with its plan to regain compliance with the Rule by September 25, 2023.

On October 17, 2023, Nasdaq granted the Company a final extension until October 31, 2023 to regain compliance with this Rule. On November 10, 2023, the Company received a letter from Nasdaq advising the Company that in light of the Company’s inability to meet the terms of the Panel’s amended decision of October 17, 2023, the Panel had determined to delist the Company’s securities from Nasdaq and suspend trading in those securities effective at the open of trading on November 13, 2023. The letter further advised that Nasdaq will complete the delisting by filing a Form 25 Notice of Delisting with the Securities and Exchange Commission, after applicable appeal periods have lapsed. The Company has appealed the decision of the Panel and paid the applicable filing fee for such appeal. On November 17, 2023, Nasdaq advised the Company that the decision of the Panel will be reviewed by the Nasdaq Listing and Hearing Review Council, and that the Company may submit a memorandum in support of its appeal no later than December 1, 2023.

As previously disclosed, in connection with the transactions contemplated by the Merger Agreement, the Company has filed a registration statement on Form S-1 for the sale of its securities in connection with the closing of the transactions contemplated by the Merger Agreement. As previously reported, the Company had intended to cure its Nasdaq listing deficiency by consummating the transactions contemplated by the Merger Agreement and the proposed public offering by October 31, 2023. The Company has advised Nasdaq that it intends to proceed with such transactions and the proposed public offering of its securities and that it intends to relist its securities on Nasdaq in connection with the closing of such transactions and such public offering. There can be no assurance that the Company will be able to consummate the Mergers and relist its securities on Nasdaq.

Risks and Uncertainties

The Company is subject to a number of risks similar to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.

Results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond the Company’s control. The Company’s business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, and geopolitical instability, such as the military conflicts in Ukraine and the Israel-Hamas war. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact the Company’s business.

Basis of Presentation

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, SeqLL, LLC and SeqLL Merger Sub. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2023 and its results of operations for the three- and nine-months ended September 30, 2023 and 2022, and changes in stockholders’ equity and cash flows for the periods presented. The results disclosed in the condensed consolidated statements of operations and comprehensive loss for the three- and nine-months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 filed with the Securities and Exchange Commission.

Fair Value Measurements

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4 – Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and requires disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1:

Observable inputs such as quoted prices in active markets.

Level 2:

Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

Level 3:

Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no assets measured at fair value on a recurring basis as of September 30, 2023.

The following table summarizes fair value measurements by level on December 31, 2022 of the Company’s assets measured at fair value on a recurring basis:

	Fair Value Measurements Using
	Fair Value		Level 1		Level 2		Level 3
U.S. government and agency obligations	$	4,036,014	$	4,036,014		-		-

There were no assets or liabilities measured at fair value on a non-recurring basis during the three- and nine- month periods ended September 30, 2023 or 2022.

The carrying values of financial instruments such as accounts receivable, net, other receivables, prepaid expenses, accounts payable, and accrued expenses approximated fair value as of September 30, 2023 and December 31, 2022 due to their short-term maturities. The carrying value of the Company’s Non-Convertible Promissory Note approximated its fair value as of September 30, 2023 and December 31, 2022.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Restricted Stock Units [Member]
Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share [Line Items]
Diluted net loss per share	13,825
Stock Options [Member]
Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share [Line Items]
Diluted net loss per share	63,648	50,098
Warrants for Common Stock [Member]
Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share [Line Items]
Diluted net loss per share	95,950	109,705

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2023

Significant Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include but are not limited to stock-based compensation expense and discount rates used to establish operating and finance lease liabilities. Actual results could differ from those estimates and changes in estimates may occur.

Inventory

Inventory

Inventory consists of finished goods, work-in-process and raw materials and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”) method. As the Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory. The Company evaluates the carrying cost of finished goods, work-in-process, and raw materials items. To the extent that such costs exceed future demand estimates and/or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the applicable inventories. Inventory consisted of the following:

	September 30,		December 31,
	2023		2022

Raw materials	$	-	$	114,175
Work in process		-		51,677
Total inventory	$	-	$	165,852

In March 2023, the Company performed a detailed evaluation of its inventory and given the lack of sales activity in prior periods, the Company has written off its remaining inventory.

Stock-based Compensation

Stock-based Compensation

The Company’s stock-based compensation program awards include stock options and restricted stock units. The fair value of stock option grants is estimated as of the date of the grant using the Black-Scholes option pricing model. The fair value of restricted stock units is based on the fair value of the Company’s common stock on the date of the grant. The fair value of the awards are then expensed over the requisite service period, generally the vesting period, for each award.

The Company’s expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the life of the option. The expected dividend yield was set to zero as the Company does not pay dividends on its common stock and there was no expectation of doing so as of the respective grant dates. The Company recognizes forfeitures related to stock-based awards as they occur.

The Company has periodically granted stock options and restricted stock units to non-employees for services pursuant to the Company’s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be cancelled. For awards granted to non-employees, compensation expense is recognized over the service period of the awards.

The assumptions used in determining the fair value of stock-based awards granted during the nine-months ended September 30, 2023 are as follows:

		September 30,
		2023
Risk-free interest rate		3.59% - 4.13%
Expected option life		6 – 6.1 years
Expected dividend yield		0%
Expected stock price volatility		57%

Segments

Segments

The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies.

Leases

Leases

In the first quarter of 2022, the Company adopted ASU No. 2016-02, Leases (Topic 842). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company classifies its leases as either finance or operating leases, with classification affecting the pattern of expense recognition in the Company’s condensed consolidated financial statements. The Company accounts for the leases of less than 12 months as short-term leases.

The Company recognizes right-of-use assets and lease liabilities that represent the net present value of future lease payments utilizing the discount rate implicit in the lease. If the implicit rate is not available, the Company uses incremental borrowing rate. The Company amortizes the right-of-use assets over the remaining terms of the specific lease.

The Company’s operating lease is included in Operating lease right-of-use asset, and Current portion of operating lease liability and Operating lease liability, less current portion in the condensed consolidated balance sheets.

The Company’s finance lease is included in Property and equipment, net, Current portion of finance lease liability and Finance lease liability, less current portion in the condensed consolidated balance sheets.

Net Loss per Share

Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of restricted stock units, options outstanding under the Company’s stock option plan, and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:

	September 30,
	2023		2022
Restricted stock units		13,825		-
Stock options		63,648		50,098
Warrants for common stock		95,950		109,705

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, or ASU 2016-13. The guidance is effective for fiscal years beginning after December 15, 2022. The Company adopted this standard on January 1, 2023, which had no material impact on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Standards

Recently Issued Accounting Standards

The Company does not believe that any recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying condensed consolidated financial statements.

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for segment reporting.

+ References + Details

- Definition

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.C.Q3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.1.Q5)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.3.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2.Q6)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//718/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Accrued Expenses (Details) - Schedule of Accrued Expenses - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accrued Expenses [Abstract]
Accrued interest	$ 358,003	$ 306,821
Accrued bonuses		135,000
Other		53,641
Accrued expenses, total	$ 358,003	$ 495,462

Significant Accounting Policies (Details)	9 Months Ended
Significant Accounting Policies (Details)	Sep. 30, 2023
Significant Accounting Policies [Abstract]
Employees contractual term	10 years

Stock-based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
Stock-based Compensation (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock-based Compensation [Line Items]
Future issuance of shares (in Shares)	10,027		10,027
Fair value of options granted (in Dollars per share)			$ 11.6
Stock-based compensation	$ 106,183	$ 66,996	$ 295,210	$ 189,905
General and administrative expenses	54,167	46,394	160,106	131,533
Research and development expenses	$ 52,016	$ 20,602	135,104	$ 58,372
Unrecognized compensation expense			639,812
Unrecognized compensation expense			$ 285,102
Weighted average period			1 year 3 months 21 days
Minimum [Member]
Stock-based Compensation [Line Items]
Weighted average period			1 year 3 months 7 days
Maximum [Member]
Stock-based Compensation [Line Items]
Weighted average period			1 year 4 months 2 days
2014 Equity Incentive Plan [Member]
Stock-based Compensation [Line Items]
Grant of options (in Shares)			87,500

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, net of allowances for doubtful accounts (in Dollars)	$ 24,507	$ 6,016
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	380,648	330,648
Common stock, shares outstanding	380,648	330,648

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies [Abstract]

Schedule of Reconciles Undiscounted Lease Liabilities to the Total Lease Liabilities Recognized

The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2023:

	Operating Lease		Finance Lease
2023 (remaining)	$	68,455	$	18,094
2024		275,875		72,375
2025		284,151		54,281
2026		292,676		-
2027		301,456		-
Thereafter		548,577		-
Total undiscounted lease liabilities	$	1,771,190	$	144,750
Less effects of discounting		279,541		20,136
Total lease liabilities	$	1,491,649	$	124,614

Stock-based Compensation (Details) - Schedule of Restricted Stock Unit Activity	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Schedule Of Restricted Stock Unit Activity Abstract
Number of Shares, Outstanding at Beginning \| shares
Weighted- Average Exercise Price per Share, Outstanding at Beginning \| $ / shares
Weighted Average Remaining Contractual Term, Outstanding at Beginning
Number of Shares, Granted \| shares	13,825
Weighted- Average Exercise Price per Share, Granted \| $ / shares	$ 25.6
Weighted Average Remaining Contractual Term, Granted	10 years
Number of Shares, Outstanding at Ending \| shares	13,825
Weighted- Average Exercise Price per Share, Outstanding at Ending \| $ / shares	$ 25.6
Weighted Average Remaining Contractual Term,Outstanding at Ending	9 years 5 months 1 day
Number of Shares, Exercisable \| shares
Weighted- Average Exercise Price per Share, Exercisable \| $ / shares
Weighted Average Remaining Contractual Term, Exercisable

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Assets Measured at Fair Value

The following table summarizes fair value measurements by level on December 31, 2022 of the Company’s assets measured at fair value on a recurring basis:

	Fair Value Measurements Using
	Fair Value		Level 1		Level 2		Level 3
U.S. government and agency obligations	$	4,036,014	$	4,036,014		-		-

Nature of Operations and Basis of Presentation (Details) - USD ($)				9 Months Ended
	Sep. 08, 2023	Feb. 15, 2023	Apr. 08, 2014	Sep. 30, 2023	Aug. 29, 2023	Dec. 31, 2022
Nature of Operations and Basis of Presentation [Line Items]
Common stock price per share (in Dollars per share)				$ 0.00001	$ 0.00001	$ 0.00001
Shares					320,000,000
Common stock shares				380,648	300,000,000	330,648
Preferred shares				0	20,000,000	0
Purchase price (in Dollars)				$ 1,000
Principal amount (in Dollars)				$ 1,375,000
Gross proceeds (in Dollars)		$ 1,800,000
Offering costs (in Dollars)		$ 300,750
Common Stock, Shares Held in Employee Trust, Shares	500,000
Percentage of shares	10.00%
Common Stock [Member]
Nature of Operations and Basis of Presentation [Line Items]
Common stock price per share (in Dollars per share)		$ 36
Shares issued		50,000
SeqLL, LLC [Member]
Nature of Operations and Basis of Presentation [Line Items]
Ownership interest, Percentage			100.00%

Notes Payable

9 Months Ended

Sep. 30, 2023

Notes Payable [Abstract]

Notes Payable

Note 7 – Notes Payable

From April 29, 2019 to April 29, 2020, the Company entered into a series of non-convertible promissory notes (the “Promissory Notes”) with St. Laurent Investments LLC amounting to $1,375,000. The Promissory Notes had a one-year term, most recently extended through July 31, 2024. The Promissory Notes bear interest accruing at the rate of 10% per annum, reduced down to 5% per annum through an amendment on October 1, 2021.

For the three months ended September 30, 2023 and 2022, interest expense on the Promissory Notes was $17,188, respectively.

For the nine months ended September 30, 2023 and 2022, interest expense on the Promissory Notes was $51,181 and $73,560, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2023

Accrued Expenses [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following:

	September 30,		December 31,
	2023		2022
Accrued interest	$	358,003	$	306,821
Accrued bonuses		-		135,000
Other		-		53,641
	$	358,003	$	495,462

Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Significant Accounting Policies [Abstract]

Significant Accounting Policies

Note 2 – Significant Accounting Policies

During the nine-month period ended September 30, 2023, there were no changes to the significant accounting policies in relation to what was described in the Annual Report on Form 10-K for the year ended December 31, 2022, other than the items noted in the Recently Adopted Accounting Standards section below.

Use of Estimates

Inventory

	September 30,		December 31,
	2023		2022

Raw materials	$	-	$	114,175
Work in process		-		51,677
Total inventory	$	-	$	165,852

In March 2023, the Company performed a detailed evaluation of its inventory and given the lack of sales activity in prior periods, the Company has written off its remaining inventory.

Stock-based Compensation

The assumptions used in determining the fair value of stock-based awards granted during the nine-months ended September 30, 2023 are as follows:

		September 30,
		2023
Risk-free interest rate		3.59% - 4.13%
Expected option life		6 – 6.1 years
Expected dividend yield		0%
Expected stock price volatility		57%

Segments

The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies.

Leases

Net Loss per Share

The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:

	September 30,
	2023		2022
Restricted stock units		13,825		-
Stock options		63,648		50,098
Warrants for common stock		95,950		109,705

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

The Company does not believe that any recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying condensed consolidated financial statements.

Common Stock Warrants (Details) - USD ($)	9 Months Ended
Common Stock Warrants (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Purchase of warrants	$ 12,162
Purchase of common stock	$ 1,590	$ 130
Warrants exercise price per share	$ 86.4
Exercise price per share	$ 124	$ 124

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2023	Nov. 17, 2023
Document Information Line Items
Entity Registrant Name	SEQLL INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		380,648
Amendment Flag	false
Entity Central Index Key	0001605888
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40760
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5319744
Entity Address, Address Line One	3 Federal Street
Entity Address, City or Town	Billerica
Entity Address, Country	MA
Entity Address, Postal Zip Code	01821
City Area Code	(781)
Local Phone Number	460-6016
Entity Interactive Data Current	Yes
Common Stock, par value $.00001 per share
Document Information Line Items
Trading Symbol	SQL
Title of 12(b) Security	Common Stock, par value $.00001 per share
Security Exchange Name	NASDAQ
Warrants to purchase Common Stock
Document Information Line Items
Trading Symbol	SQLLW
Title of 12(b) Security	Warrants to purchase Common Stock
Security Exchange Name	NASDAQ

Significant Accounting Policies (Details) - Schedule of Fair Value of Share-Based Awards Granted	9 Months Ended
	Sep. 30, 2023
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Expected dividend yield	0.00%
Expected stock price volatility	57.00%
Minimum [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Risk-free interest rate	3.59%
Expected option life	6 years
Maximum [Member]
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Risk-free interest rate	4.13%
Expected option life	6 years 1 month 6 days

Common Stock Warrants (Details) - Schedule of Outstanding Warrants to Purchase Common Stock	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Total	95,950
10/17/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Oct. 17, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	29
Exercise Price \| $ / shares	$ 124
Expiration Date	Oct. 16, 2023
11/2/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 02, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	24
Exercise Price \| $ / shares	$ 124
Expiration Date	Nov. 01, 2023
11/9/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 09, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	24
Exercise Price \| $ / shares	$ 124
Expiration Date	Nov. 08, 2023
11/16/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 16, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	24
Exercise Price \| $ / shares	$ 124
Expiration Date	Nov. 15, 2023
11/29/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 29, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	24
Exercise Price \| $ / shares	$ 124
Expiration Date	Nov. 28, 2023
12/21/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 21, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	24
Exercise Price \| $ / shares	$ 124
Expiration Date	Dec. 20, 2023
12/27/2018 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 27, 2018
Number of Shares Issuable Upon Exercise of Outstanding Warrants	24
Exercise Price \| $ / shares	$ 124
Expiration Date	Dec. 26, 2023
1/31/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Jan. 31, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	48
Exercise Price \| $ / shares	$ 124
Expiration Date	Jan. 30, 2024
2/7/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 07, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	41
Exercise Price \| $ / shares	$ 124
Expiration Date	Feb. 06, 2024
2/21/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 21, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	41
Exercise Price \| $ / shares	$ 124
Expiration Date	Feb. 20, 2024
3/20/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 20, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	84
Exercise Price \| $ / shares	$ 124
Expiration Date	Mar. 18, 2024
4/8/2019 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Apr. 08, 2019
Number of Shares Issuable Upon Exercise of Outstanding Warrants	48
Exercise Price \| $ / shares	$ 124
Expiration Date	Apr. 06, 2024
11/19/2020 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 19, 2020
Number of Shares Issuable Upon Exercise of Outstanding Warrants	1,333
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
11/19/2020 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Nov. 19, 2020
Number of Shares Issuable Upon Exercise of Outstanding Warrants	213
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
1/8/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Jan. 08, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	333
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
1/11/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Jan. 11, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	667
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
2/13/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 13, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	333
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
3/16/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 16, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	267
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
3/16/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Mar. 16, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	333
Exercise Price \| $ / shares	$ 164
Expiration Date	Jun. 30, 2024
8/31/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 31, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	87,975
Exercise Price \| $ / shares	$ 170
Expiration Date	Aug. 31, 2026
8/31/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 31, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	3,825
Exercise Price \| $ / shares	$ 187
Expiration Date	Aug. 26, 2026
9/29/2021 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Sep. 29, 2021
Number of Shares Issuable Upon Exercise of Outstanding Warrants	236
Exercise Price \| $ / shares	$ 187
Expiration Date	Aug. 26, 2026

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Significant Accounting Policies [Abstract]

Schedule of Inventory

Inventory consisted of the following:

	September 30,		December 31,
	2023		2022

Raw materials	$	-	$	114,175
Work in process		-		51,677
Total inventory	$	-	$	165,852

Schedule of Fair Value of Share-Based Awards Granted

The assumptions used in determining the fair value of stock-based awards granted during the nine-months ended September 30, 2023 are as follows:

		September 30,
		2023
Risk-free interest rate		3.59% - 4.13%
Expected option life		6 – 6.1 years
Expected dividend yield		0%
Expected stock price volatility		57%

Schedule of Diluted Net Loss Per Share

The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive:

	September 30,
	2023		2022
Restricted stock units		13,825		-
Stock options		63,648		50,098
Warrants for common stock		95,950		109,705

- Definition

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2023

Schedule of Outstanding Payables

	September 30,		December 31,
	2023		2022
Genomic Diagnostic Technologies	$	-	$	925
St. Laurent Institute		-		232,418
St. Laurent Realty, Inc.		7,558		7,558
	$	7,558	$	240,901

Commitments and Contingencies (Details) - Schedule of Reconciles Undiscounted Lease Liabilities to the Total Lease Liabilities Recognized	Sep. 30, 2023 USD ($)
Operating Lease [Member]
Commitments and Contingencies (Details) - Schedule of Reconciles Undiscounted Lease Liabilities to the Total Lease Liabilities Recognized [Line Items]
Operating Lease, 2023 (remaining)	$ 68,455
Operating Lease, 2024	275,875
Operating Lease, 2025	284,151
Operating Lease, 2026	292,676
Operating Lease, 2027	301,456
Operating Lease, Thereafter	548,577
Operating Lease, Total undiscounted lease liabilities	1,771,190
Operating Lease, Less effects of discounting	279,541
Operating Lease, Total lease liabilities	1,491,649
Finance Lease [Member]
Commitments and Contingencies (Details) - Schedule of Reconciles Undiscounted Lease Liabilities to the Total Lease Liabilities Recognized [Line Items]
Finance Lease, 2023 (remaining)	18,094
Finance Lease, 2024	72,375
Finance Lease, 2025	54,281
Finance Lease, 2026
Finance Lease, 2027
Finance Lease, Thereafter
Finance Lease, Total undiscounted lease liabilities	144,750
Finance Lease, Less effects of discounting	20,136
Finance Lease, Total lease liabilities	$ 124,614

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Sales				$ 1,177
Grant revenue				77,482
Total revenue				78,659
Cost of sales				690
Gross profit				77,969
Operating expenses
Research and development	411,332	428,771	1,769,770	1,129,286
General and administrative	877,612	489,729	2,721,405	1,700,340
Total operating expenses	1,288,944	918,500	4,491,175	2,829,626
Operating loss	(1,288,944)	(918,500)	(4,491,175)	(2,751,657)
Other (income) and expenses
Investment income	(43,613)	(9,981)	(167,018)	(18,457)
Unrealized loss (gain) on marketable securities		242		(54,266)
Realized loss on marketable securities				106,324
Interest expense	22,337	17,188	61,991	73,560
Net loss	(1,267,668)	(925,949)	(4,386,148)	(2,858,818)
Other comprehensive income
Reclassification adjustment for net gains included in net loss			(22,451)
Net change			(22,451)
Total comprehensive loss	$ (1,267,668)	$ (925,949)	$ (4,408,599)	$ (2,858,818)
Net loss per share - basic and diluted (in Dollars per share)	$ (3.33)	$ (2.8)	$ (11.78)	$ (8.65)
Weighted average common shares - basic and diluted (in Shares)	380,648	330,648	372,406	330,648